Vector Labs Ab04908-10.3 Anti-CD22 [G5/44 (Inotuzumab)], Human IgG1, Fc Silent™, kappa (100 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: G5/44 (Inotuzumab)
Heavy Chain Modification: Fc Silent™
Synonyms: BL-CAM; SIGLEC2; Siglec-2; B-cell receptor CD22; B-lymphocyte cell adhesion molecule; Sialic acid-binding Ig-like lectin 2; T-cell surface antigen Leu-14; CMC-544; BESPONSA; g5/44 gHd/gLa; h5/44; humanized m5/44
Amount: 100 μg
Application Codes Clone: Therapeutic; SPR; FC; ELISA; WB
Shipping Temperature: Wet Ice
Origin Pub PMID: 15693135
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG4
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human format, created for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody binds human CD22. The antibody recognises epitope A located in the first N-terminal domain of CD22.
Application Notes: The binding affinity of the original format of the antibody to human CD22 was measured by surface plasmon resonance (Kd= 235 pM). The binding of the original format of the antibody to CD22 expressed on the surface of human B-lymphoma cells was further confirmed by flow cytometry. CMC-544 is a variant of G5/44, covalently linked to CalichDMH via an acid-labile 4-(4'-acetylphenoxy) butanoic acid (AcBut) linker. The binding affinity of CMC-544 to human CD22 was measured by surface plasmon resonance (Kd= 200 pM). The binding of CMC-544 to CD22 expressed on the surface of human B-lymphoma cells was further confirmed by flow cytometry. CMC-544 specifically recognizes CD22 on human B cells but not on murine, rat, canine, porcine, or primate (cynomolgus and rhesus) B cells. CMC544 exerted potent cytotoxicity against CD22 B-cell lymphoma (BCL) cell lines (inhibitory concentration of 50%: 6-600 pM CalichDMH). CMC-544 caused a potent inhibition of growth of small but established BCL xenografts leading to cures (therapeutic index > 10). CMC-544 prevented the establishment of BCL xenografts and also caused regression of large BCLs (> 1.5 g tumor mass) (DiJoseph et al., 2004; PMID: 14615373). Incubation of Ramos BCLs in vitro with CalichDM conjugated to g5/44 via either acid-labile or acid-stable linkers inhibited their growth in vitro (DiJoseph et al., 2005; PMID: 15693135). The antibody detected the human CD22 by western blot analysis (Laszlo et al., 2024; PMID: 37170642).

Product Class:	Purified
Clone ID:	G5/44 (Inotuzumab)
Heavy Chain Modification:	Fc Silent™
Synonyms:	BL-CAM; SIGLEC2; Siglec-2; B-cell receptor CD22; B-lymphocyte cell adhesion molecule; Sialic acid-binding Ig-like lectin 2; T-cell surface antigen Leu-14; CMC-544; BESPONSA; g5/44 gHd/gLa; h5/44; humanized m5/44
Amount:	100 μg
Application Codes Clone:	Therapeutic; SPR; FC; ELISA; WB
Shipping Temperature:	Wet Ice
Origin Pub PMID:	15693135
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG4
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human format, created for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody binds human CD22. The antibody recognises epitope A located in the first N-terminal domain of CD22.
Application Notes:	The binding affinity of the original format of the antibody to human CD22 was measured by surface plasmon resonance (Kd= 235 pM). The binding of the original format of the antibody to CD22 expressed on the surface of human B-lymphoma cells was further confirmed by flow cytometry. CMC-544 is a variant of G5/44, covalently linked to CalichDMH via an acid-labile 4-(4'-acetylphenoxy) butanoic acid (AcBut) linker. The binding affinity of CMC-544 to human CD22 was measured by surface plasmon resonance (Kd= 200 pM). The binding of CMC-544 to CD22 expressed on the surface of human B-lymphoma cells was further confirmed by flow cytometry. CMC-544 specifically recognizes CD22 on human B cells but not on murine, rat, canine, porcine, or primate (cynomolgus and rhesus) B cells. CMC544 exerted potent cytotoxicity against CD22 B-cell lymphoma (BCL) cell lines (inhibitory concentration of 50%: 6-600 pM CalichDMH). CMC-544 caused a potent inhibition of growth of small but established BCL xenografts leading to cures (therapeutic index > 10). CMC-544 prevented the establishment of BCL xenografts and also caused regression of large BCLs (> 1.5 g tumor mass) (DiJoseph et al., 2004; PMID: 14615373). Incubation of Ramos BCLs in vitro with CalichDM conjugated to g5/44 via either acid-labile or acid-stable linkers inhibited their growth in vitro (DiJoseph et al., 2005; PMID: 15693135). The antibody detected the human CD22 by western blot analysis (Laszlo et al., 2024; PMID: 37170642).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews